Homology Medicines (STU:35H) EBIT : €-85.60 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines EBIT?

Homology Medicines's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was €-8.63 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-85.60 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Homology Medicines's annualized ROC % for the quarter that ended in Dec. 2023 was -149.13%. Homology Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -366.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Homology Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 118.71%.

Homology Medicines EBIT Historical Data

The historical data trend for Homology Medicines's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines EBIT Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-98.95

-107.08

-84.92

-125.82

-84.46

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-32.56	-25.70	-28.44	-22.83	-8.63

Competitive Comparison of Homology Medicines's EBIT

For the Biotechnology subindustry, Homology Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Homology Medicines's EV-to-EBIT falls into.

Homology Medicines EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-85.60 Mil.

Homology Medicines (STU:35H) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Homology Medicines's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-34.532 * ( 1 - 0% )	/	( (39.229	+	7.082)	/ 2 )
=	-34.532	/	23.1555
=	-149.13 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	131.239	-	15.792	-	( 96.79	-	max(0, 23.699	-	99.917	+	96.79	))
=	39.229

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	77.545	-	4.126	-	( 75.793	-	max(0, 10.612	-	76.949	+	75.793	))
=	7.082

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Homology Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-34.532	/	( ( (18.244 + max(-18.906, 0))	+	(0.596 + max(-8.247, 0)) )	/	2 )
=	-34.532	/	( ( 18.244	+	0.596 )	/	2 )
=	-34.532	/	9.42
=	-366.58 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.127)	-	(15.792	+	0	+	6.241)
=	-18.906

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.156)	-	(4.126	+	0	+	5.277)
=	-8.247

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Homology Medicines's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-85.597	/	-72.108
	=	118.71 %

Homology Medicines EBIT Related Terms

Thank you for viewing the detailed overview of Homology Medicines's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (STU:35H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

FIXX:USA

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines